Skip to main content
. 2014 Nov 4;9(11):e111515. doi: 10.1371/journal.pone.0111515

Figure 3. Efficacy of shRNA targeting DDR1 on BXPC3 tumor growth.

Figure 3

(a) BXPC3 cells untreated (•), NT shRNA (▪) and DDR1 shRNA5 (Δ) were implanted in ICR-SCID mice and tumor growth was monitored up to 28 days. (b) On day 28, when compared to untreated and NT shRNA groups, the tumors in DDR1 shRNA5 group was the smallest as measured by the tumor volume (N = 10). The calculated percent inhibition in tumor growth in DDR1 shRNA group was 50.7% (***, p<0.0001) and 43.2% (**, p<0.0052) when compared to parental and NT shRNA groups, respectively. Tumors were harvested and DDR1 expression was confirmed by (c) immunohistochemistry and (d) western blot.